
Eleftherios P Mamounas

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/6929700/publications.pdf Version: 2024-02-01



#	Article	IF	CITATIONS
1	Abstract 532: Association of pCR and the 8-gene signature: NRG Oncology/NSABP B-41. , 2021, , .		0
2	Comparison of Radiation With or Without Concurrent Trastuzumab for HER2-Positive Ductal Carcinoma In Situ Resected by Lumpectomy: A Phase III Clinical Trial. Journal of Clinical Oncology, 2021, 39, 2367-2374.	0.8	16
3	Primary results of NRG Oncology / NSABP B-43: Phase III trial comparing concurrent trastuzumab (T) and radiation therapy (RT) with RT alone for women with HER2-positive ductal carcinoma in situ (DCIS) after lumpectomy Journal of Clinical Oncology, 2020, 38, 508-508.	0.8	5
4	Long-term primary results of accelerated partial breast irradiation after breast-conserving surgery for early-stage breast cancer: a randomised, phase 3, equivalence trial. Lancet, The, 2019, 394, 2155-2164.	6.3	319
5	Use of letrozole after aromatase inhibitor-based therapy in postmenopausal breast cancer (NRG) Tj ETQq1 1 0.784 The, 2019, 20, 88-99.	4314 rgBT 5.1	/Overlock 1 108
6	Patient-reported outcomes (PROs) in NRG oncology/NSABP B-39/RTOG 0413: A randomized phase III study of conventional whole breast irradiation (WBI) versus partial breast irradiation (PBI) in stage 0, I, or II breast cancer Journal of Clinical Oncology, 2019, 37, 508-508.	0.8	11
7	nkG Oncology/NSABP B-51/RTOG 1304: Phase III trial to determine if chest wall and regional nodal radiotherapy (CWRNRT) post mastectomy (Mx) or the addition of RNRT to whole breast RT post breast-conserving surgery (BCS) reduces invasive breast cancer recurrence-free interval (IBCR-FI) in patients (pts) with pathologically positive axillary (PPAx) nodes who are ypNO after neoadjuvant	0.8	38
8	21-Gene Recurrence Score for prognosis and prediction of taxane benefit after adjuvant chemotherapy plus endocrine therapy: results from NSABP B-28/NRG Oncology. Breast Cancer Research and Treatment, 2018, 168, 69-77.	1.1	36
9	Efficacy of Chemotherapy for ER-Negative and ER-Positive Isolated Locoregional Recurrence of Breast Cancer: Final Analysis of the CALOR Trial. Journal of Clinical Oncology, 2018, 36, 1073-1079.	0.8	102
10	Optimizing Surgical Management of the Axilla After Neoadjuvant Chemotherapy: An Evolving Story. Annals of Surgical Oncology, 2018, 25, 2124-2126.	0.7	9
11	Omitting Surgery in Complete Responders After Neoadjuvant Chemotherapy: The Quest Continues. Annals of Surgical Oncology, 2018, 25, 3119-3122.	0.7	7
12	NRG Oncology/NSABP B-31: Stromal tumor infiltrating lymphocytes (sTILs) and outcomes in early-stage HER2-positive breast cancer (BC) Journal of Clinical Oncology, 2018, 36, 12010-12010.	0.8	2
13	Intrinsic subtypes of HER2-positive breast cancer and their associations with pathologic complete response (pCR) and outcomes: Findings from NSABP B-41, a randomized neoadjuvant trial Journal of Clinical Oncology, 2018, 36, 580-580.	0.8	4
14	NRG Oncology/NSABP B-51/RTOG 1304: Phase III trial to determine if chest wall and regional nodal radiotherapy (CWRNRT) post mastectomy (Mx) or the addition of RNRT to breast RT post breast-conserving surgery (BCS) reduces invasive breast cancer recurrence-free interval (IBCR-FI) in patients (pts) with positive axillary (PAx) nodes who are ypN0 after neoadjuvant chemotherapy (NC)	0.8	4
15	NSABP 8-59/CBC 90-CeparDouze: A randomized double-blind phase III clinical trial of neoadjuvant chemotherapy (NAC) with atezolizumab or placebo in Patients (pts) with triple negative breast cancer (TNBC) followed by adjuvant atezolizumab or placebo Journal of Clinical Oncology, 2018, 36, TPS603-TPS603.	0.8	6
16	NRG Oncology BR005: Phase II trial assessing accuracy of tumor bed biopsies (Bx) in predicting pathologic response in patients (Pts) with clinical/radiological complete response (CR) after neoadjuvant chemotherapy (NCT) in order to explore the feasibility of breast-conserving treatment (BCT) without surgery Journal of Clinical Oncology, 2018, 36, TPS604-TPS604.	0.8	10
17	Current approach of the axilla in patients with early-stage breast cancer. Lancet, The, 2017, , .	6.3	53
18	21-Gene Recurrence Score and Locoregional Recurrence in Node-Positive/ER-Positive Breast Cancer Treated With Chemo-Endocrine Therapy. Journal of the National Cancer Institute, 2017, 109, djw259.	3.0	116

#	Article	IF	CITATIONS
19	Poor Prognosis After Second Locoregional Recurrences in the CALOR Trial. Annals of Surgical Oncology, 2017, 24, 398-406.	0.7	29
20	Epirubicin With Cyclophosphamide Followed by Docetaxel With Trastuzumab and Bevacizumab as Neoadjuvant Therapy for HER2-Positive Locally Advanced Breast Cancer or as Adjuvant Therapy for HER2-Positive Pathologic Stage III Breast Cancer: A Phase II Trial of the NSABP Foundation Research Group, FB-5. Clinical Breast Cancer. 2017, 17, 48-54, e3. Long-Term Follow-Up of Cardiac Function and Quality of Life for Patients in NSABP Protocol B-31/NRG	1,1	8
21	Oncology: A Randomized Trial Comparing the Safety and Efficacy of Doxorubicin and Cyclophosphamide (AC) Followed by Paclitaxel With AC Followed by Paclitaxel and Trastuzumab in Patients With Node-Positive Breast Cancer With Tumors Overexpressing Human Epidermal Growth	0.8	55
22	NRG Oncology/NSABP B-51/RTOG 1304: Phase III trial to determine if chest wall and regional nodal radiotherapy (CWRNRT) post mastectomy (Mx) or the addition of RNRT to breast RT post breast-conserving surgery (BCS) reduces invasive breast cancer recurrence free interval (IBCRFI) in patients (pts) with positive axillary (PAx) nodes who are ypN0 after neoadjuvant chemotherapy (NC)	0.8	9
23	Prognostic Impact of the Combination of Recurrence Score and Quantitative Estrogen Receptor Expression (<i>ESR1</i>) on Predicting Late Distant Recurrence Risk in Estrogen Receptor–Positive Breast Cancer After 5 Years of Tamoxifen: Results From NRG Oncology/National Surgical Adjuvant Breast and Bowel Project B-28 and B-14. Journal of Clinical Oncology, 2016, 34, 2350-2358.	0.8	71
24	Optimal Management of the Axilla. Advances in Surgery, 2016, 50, 29-40.	0.6	9
25	Neoadjuvant Systemic Therapy for Breast Cancer: Factors Influencing Surgeons' Referrals. Annals of Surgical Oncology, 2016, 23, 3510-3517.	0.7	6
26	Anastrozole versus tamoxifen in postmenopausal women with ductal carcinoma in situ undergoing lumpectomy plus radiotherapy (NSABP B-35): a randomised, double-blind, phase 3 clinical trial. Lancet, The, 2016, 387, 849-856.	6.3	148
27	Patient-reported outcomes with anastrozole versus tamoxifen for postmenopausal patients with ductal carcinoma in situ treated with lumpectomy plus radiotherapy (NSABP B-35): a randomised, double-blind, phase 3 clinical trial. Lancet, The, 2016, 387, 857-865.	6.3	67
28	Time-Varying Effects of Breast Cancer Adjuvant Systemic Therapy. Journal of the National Cancer Institute, 2016, 108, djv304.	3.0	19
29	Interim joint analysis of the ABC (anthracyclines in early breast cancer) phase III trials (USOR 06-090,) Tj ETQq1 anthracycline/taxane-based chemotherapy regimens (TaxAC) in women with high-risk, HER2-negative breast cancer Journal of Clinical Oncology. 2016, 34, 1000-1000.	1 0.78431 0.8	4 rgBT /Overla 12
30	Evaluation of lapatinib as a component of neoadjuvant therapy for HER2+ operable breast cancer: 5-year outcomes of NSABP protocol B-41 Journal of Clinical Oncology, 2016, 34, 501-501.	0.8	19
31	NRG Oncology/NSABP B-51/RTOG 1304: Phase III trial to determine if chest wall and regional nodal radiotherapy (CWRNRT) post mastectomy (Mx) or the addition of RNRT to breast RT post breast-conserving surgery (BCS) reduces invasive breast cancer recurrence free interval (IBCRFI) in patients (pts) with positive axillary (PAx) nodes who are ypN0 after neoadjuvant chemotherapy (NC)	0.8	0
32	Agreement between MRI and pathologic breast tumor size after neoadjuvant chemotherapy, and comparison with alternative tests: individual patient data meta-analysis. BMC Cancer, 2015, 15, 662.	1.1	106
33	Impact of Neoadjuvant Chemotherapy on Locoregional Surgical Treatment of Breast Cancer. Annals of Surgical Oncology, 2015, 22, 1425-1433.	0.7	58
34	Lumpectomy margins: Everything old is new again?. Surgical Oncology, 2015, 24, 5-8.	0.8	0
35	Neoadjuvant plus adjuvant bevacizumab in early breast cancer (NSABP B-40 [NRG Oncology]): secondary outcomes of a phase 3, randomised controlled trial. Lancet Oncology, The, 2015, 16, 1037-1048.	5.1	138
36	Neoadjuvant Therapy for Early-Stage Breast Cancer: A Model for Individualizing Outcomes and Tailoring Locoregional and Systemic Therapy. Oncology, 2015, 29, 839-40, 846.	0.4	5

#	Article	IF	CITATIONS
37	The importance of systemic therapy in minimizing local recurrence after breastâ€conserving surgery: The NSABP experience. Journal of Surgical Oncology, 2014, 110, 45-50.	0.8	36
38	Trastuzumab Plus Adjuvant Chemotherapy for Human Epidermal Growth Factor Receptor 2–Positive Breast Cancer: Planned Joint Analysis of Overall Survival From NSABP B-31 and NCCTG N9831. Journal of Clinical Oncology, 2014, 32, 3744-3752.	0.8	771
39	Pathological complete response and long-term clinical benefit in breast cancer: the CTNeoBC pooled analysis. Lancet, The, 2014, 384, 164-172.	6.3	3,224
40	Timing of Determining Axillary Lymph Node Status When Neoadjuvant Chemotherapy is Used. Current Oncology Reports, 2014, 16, 364.	1.8	18
41	Chemotherapy for isolated locoregional recurrence of breast cancer (CALOR): a randomised trial. Lancet Oncology, The, 2014, 15, 156-163.	5.1	171
42	The Impact of Neoadjuvant Chemotherapy on Local-Regional Treatment of Breast Cancer. Current Breast Cancer Reports, 2013, 5, 106-117.	0.5	1
43	Lapatinib as a component of neoadjuvant therapy for HER2-positive operable breast cancer (NSABP) Tj ETQq1 1 (0.784314 5.1	rg₿Ţ /Over o 332
44	Meta-Analysis of Magnetic Resonance Imaging in Detecting Residual Breast Cancer After Neoadjuvant Therapy. Journal of the National Cancer Institute, 2013, 105, 321-333.	3.0	298
45	Predictors of Locoregional Recurrence After Neoadjuvant Chemotherapy: Results From Combined Analysis of National Surgical Adjuvant Breast and Bowel Project B-18 and B-27. Journal of Clinical Oncology, 2012, 30, 3960-3966.	0.8	473
46	Meta-analysis of the association of breast cancer subtype and pathologic complete response to neoadjuvant chemotherapy. European Journal of Cancer, 2012, 48, 3342-3354.	1.3	410
47	Four-Year Follow-Up of Trastuzumab Plus Adjuvant Chemotherapy for Operable Human Epidermal Growth Factor Receptor 2–Positive Breast Cancer: Joint Analysis of Data From NCCTG N9831 and NSABP B-31. Journal of Clinical Oncology, 2011, 29, 3366-3373.	0.8	646
48	Effect of Occult Metastases on Survival in Node-Negative Breast Cancer. New England Journal of Medicine, 2011, 364, 412-421.	13.9	399
49	Long-Term Outcomes of Invasive Ipsilateral Breast Tumor Recurrences After Lumpectomy in NSABP B-17 and B-24 Randomized Clinical Trials for DCIS. Journal of the National Cancer Institute, 2011, 103, 478-488.	3.0	660
50	Association Between the 21-Gene Recurrence Score Assay and Risk of Locoregional Recurrence in Node-Negative, Estrogen Receptor–Positive Breast Cancer: Results From NSABP B-14 and NSABP B-20. Journal of Clinical Oncology, 2010, 28, 1677-1683.	0.8	538
51	Morbidity results from the NSABP Bâ€32 trial comparing sentinel lymph node dissection versus axillary dissection. Journal of Surgical Oncology, 2010, 102, 111-118.	0.8	387
52	Sentinel-lymph-node resection compared with conventional axillary-lymph-node dissection in clinically node-negative patients with breast cancer: overall survival findings from the NSABP B-32 randomised phase 3 trial. Lancet Oncology, The, 2010, 11, 927-933.	5.1	1,477
53	Prognosis After Ipsilateral Breast Tumor Recurrence and Locoregional Recurrences in Patients Treated by Breast-Conserving Therapy in Five National Surgical Adjuvant Breast and Bowel Project Protocols of Node-Negative Breast Cancer. Journal of Clinical Oncology, 2009, 27, 2466-2473.	0.8	397
54	Benefit From Exemestane As Extended Adjuvant Therapy After 5 Years of Adjuvant Tamoxifen: Intention-to-Treat Analysis of the National Surgical Adjuvant Breast and Bowel Project B-33 Trial. Journal of Clinical Oncology, 2008, 26, 1965-1971.	0.8	317

#	Article	IF	CITATIONS
55	Technical outcomes of sentinel-lymph-node resection and conventional axillary-lymph-node dissection in patients with clinically node-negative breast cancer: results from the NSABP B-32 randomised phase III trial. Lancet Oncology, The, 2007, 8, 881-888.	5.1	915
56	Sequential Preoperative or Postoperative Docetaxel Added to Preoperative Doxorubicin Plus Cyclophosphamide for Operable Breast Cancer: National Surgical Adjuvant Breast and Bowel Project Protocol B-27. Journal of Clinical Oncology, 2006, 24, 2019-2027.	0.8	850
57	Prognosis After Ipsilateral Breast Tumor Recurrence and Locoregional Recurrences in Five National Surgical Adjuvant Breast and Bowel Project Node-Positive Adjuvant Breast Cancer Trials. Journal of Clinical Oncology, 2006, 24, 2028-2037.	0.8	418
58	New issues in breast cancer surgical management. , 2006, , 115-161.		2
59	Paclitaxel After Doxorubicin Plus Cyclophosphamide As Adjuvant Chemotherapy for Node-Positive Breast Cancer: Results From NSABP B-28. Journal of Clinical Oncology, 2005, 23, 3686-3696.	0.8	585
60	Sentinel Node Biopsy After Neoadjuvant Chemotherapy in Breast Cancer: Results From National Surgical Adjuvant Breast and Bowel Project Protocol B-27. Journal of Clinical Oncology, 2005, 23, 2694-2702.	0.8	492
61	Trastuzumab plus Adjuvant Chemotherapy for Operable HER2-Positive Breast Cancer. New England Journal of Medicine, 2005, 353, 1673-1684.	13.9	4,956
62	Patterns of Locoregional Failure in Patients With Operable Breast Cancer Treated by Mastectomy and Adjuvant Chemotherapy With or Without Tamoxifen and Without Radiotherapy: Results From Five National Surgical Adjuvant Breast and Bowel Project Randomized Clinical Trials. Journal of Clinical Oncology, 2004, 22, 4247-4254.	0.8	348
63	The Effect on Tumor Response of Adding Sequential Preoperative Docetaxel to Preoperative Doxorubicin and Cyclophosphamide: Preliminary Results From National Surgical Adjuvant Breast and Bowel Project Protocol B-27. Journal of Clinical Oncology, 2003, 21, 4165-4174.	0.8	1,018
64	Tamoxifen, Radiation Therapy, or Both for Prevention of Ipsilateral Breast Tumor Recurrence After Lumpectomy in Women With Invasive Breast Cancers of One Centimeter or Less. Journal of Clinical Oncology, 2002, 20, 4141-4149.	0.8	580
65	Ipsilateral Breast Tumor Recurrence After Lumpectomy: Is It Time to Take the Bull by the Horns?. Journal of Clinical Oncology, 2001, 19, 3798-3800.	0.8	12
66	Prevention of invasive breast cancer in women with ductal carcinoma in situ: An update of the National Surgical Adjuvant Breast and Bowel Project experience. Seminars in Oncology, 2001, 28, 400-418.	0.8	463
67	Preoperative Chemotherapy in Patients With Operable Breast Cancer: Nine-Year Results From National Surgical Adjuvant Breast and Bowel Project B-18. Journal of the National Cancer Institute Monographs, 2001, 2001, 96-102.	0.9	1,100
68	Prevention of invasive breast cancer in women with ductal carcinoma in situ: An update of the national surgical adjuvant breast and bowel project experience. Seminars in Oncology, 2001, 28, 400-418.	0.8	339
69	Tamoxifen in treatment of intraductal breast cancer: National Surgical Adjuvant Breast and Bowel Project B-24 randomised controlled trial. Lancet, The, 1999, 353, 1993-2000.	6.3	957
70	Pathologic findings from the national surgical adjuvant breast project (NSABP) protocol B-17: Intraductal carcinoma (ductal carcinoma in situ). Cancer, 1995, 76, 2385-2387.	2.0	26
71	Response—blunting the counterpoint. Cancer, 1995, 75, 1223-1227.	2.0	14
72	Lumpectomy Compared with Lumpectomy and Radiation Therapy for the Treatment of Intraductal Breast Cancer. New England Journal of Medicine, 1993, 328, 1581-1586.	13.9	707